Participated · Seed · Mar 2026

ImmuneBridge develops a cell therapy screening and manufacturing platform that combines machine-learning-enabled donor selection with a proprietary small molecule that preserves stem-cell pluripotency through repeated replications. This approach enables differentiation into T cells, NK cells, macrophages, or neutrophils and can produce thousands of high-quality doses from a single donor versus the industry standard of tens of doses. The company is shifting to a "picks and shovels" model by licensing its platform to external co-development partners, from startups to large pharma, and is already working with over a dozen collaborators. Following its recent financing, ImmuneBridge promoted Dr. Nina Horowitz to CEO and appointed Dr. Rui Tostoes as CTO to lead the scale-up of manufacturing. Financially, the company raised $7.7M in a second seed round led by NFX, bringing total seed funding to nearly $20M. ImmuneBridge aims to advance initial human trials in 2028 and bring 10 therapies to the clinic within the next decade.

Participated · Seed · Jul 2024

ImmuneAGE Bio has built a drug-discovery platform that targets hematopoietic stem cells (HSCs) in the bone marrow to rejuvenate the entire immune system. The platform enables large-scale ex vivo combinatorial drug screening for geroprotective cocktails and reportedly achieves 1,000x expansion of HSCs, a >70x improvement over prior efforts. The company is advancing three programs: IA-101 (an oral small-molecule immune booster for respiratory infections and vaccine response in elderly patients), IA-201 (an ex vivo immune-rejuvenation cocktail for peripheral mobilized HSCs targeting chemotherapy recovery and bone marrow transplantation), and IA-301 (an HSC expansion platform for bone marrow transplantation and other immune cell types such as T cells). ImmuneAGE has raised $2M to date and is now raising a seed round to further advance these programs. The company operates from San Juan, Puerto Rico and Lausanne, Switzerland and collaborates with teams at the University of Oxford and University of Lausanne.

Participated · Equity · Jan 2024

Reservoir Neuroscience is an Emeryville, CA-based, early-stage venture-backed biotech led by co-founders Aaron Friedman and Vlad Senatorov. The company is advancing a novel class of drug compounds designed to restore health to the brain’s blood vessels to rejuvenate the aging brain. It targets brain vascular pathology that becomes damaged and dysfunctional with aging and drives inflammation and neurodegenerative disease outcomes. Reservoir positions this vascular pathology as a biomarker that defines a patient segment and a previously untreated target. The firm intends to use its new financing to develop these compounds further. Company leadership states that treating underlying vascular problems could address a major risk factor for neurodegenerative disease and may offer broader brain-health and systemic benefits.

Participated · Series A · Aug 2023

KetoSwiss develops products aimed at improving brain energetics, a common denominator in many neurological and psychiatric diseases. Its first flagship medical food for migraine, MigraKet by Brain Ritual, pairs ketone bodies with micronutrients essential for brain energy metabolism. MigraKet is clinically tested, patent-protected, and is planned to enter the U.S. market at the end of 2023. The company is led by CEO and Founder Dr. Elena Gross and is based in Basel, Switzerland. KetoSwiss raised $4.8M in the second closing of a Pre-Series A financing and will use the funds to expand R&D and clinical development efforts.